Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05422794 |
| Title | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer |
| Recruitment | Suspended |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | National Cancer Institute (NCI) |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | United States | Details | |
| Vanderbilt Breast Center at One Hundred Oaks | Nashville | Tennessee | 37204 | United States | Details |